直肠结肠切除术和使用硫酸葡聚糖钠的回肠贮袋肛门吻合术后贮袋炎大鼠模型
May 31st, 2024
1.2K views
该协议描述了建立贮袋炎大鼠模型的方法。回肠袋模型是通过使用显微外科技术进行回肠袋肛门吻合术 （IPAA） 手术创建的。手术后，大鼠用 4% 葡聚糖硫酸钠 （DSS） 治疗 4 d。
由于对贮袋炎进行临床试验存在挑战，动物模型可以作为研究贮袋炎药物及其机制的宝贵工具。该协议描述了建立贮袋炎大鼠模型的方法。这种贮袋炎的实验动物模型为研究该病的发病机制和治疗提供了基础。
凭借以前在小鼠喂养和 IPAA 手术建模方面的经验，将学习曲线压缩到大约 10 名受试者是可行的。此过程的一个关键步骤是 J 型贮袋的构建和吻合。术后管理在成功建模中也起着关键作用。
大鼠贮袋炎模型的成功建立为后续的药物和机制研究提供了坚实的平台。我们的团队将始终致力于研究贮袋炎的发病机制和治疗药物的机制。
概述
本协议描述了小鼠袋炎模型的建立，这对于研究该疾病的发病机制和治疗至关重要。该模型通过回肠-肛门吻合术（IPAA）手术创建，随后使用硫酸盐右旋糖酐（DSS）进行治疗。
关键研究组成部分
科学领域
- 神经科学
- 生物学
- 动物模型
背景
- 袋炎是一种在临床试验中难以研究的疾病。
- 动物模型为袋炎机制提供了宝贵的见解。
- 小鼠模型允许有效调查袋炎的治疗方法。
- 之前使用IPAA手术的经验有助于模型的建立。
研究目的
- 创建一个可靠的袋炎研究小鼠模型。
- 了解袋炎的发病机制。
- 评估该疾病的潜在治疗方法。
所用方法
- 通过IPAA手术建立小鼠模型。
- 术后管理以确保模型的成功。
- 使用4%硫酸盐右旋糖酐（DSS）进行4天的治疗。
- 利用显微外科技术以确保精确。
主要结果
- 成功建立了小鼠袋炎模型。
- 模型的可行性得到证明，学习曲线降低。
- 关于袋炎的发病机制和治疗的见解。
- 使用此模型进行进一步研究的潜力。
结论
- 小鼠模型是袋炎研究的宝贵工具。
- IPAA手术和DSS治疗是建模的有效方法。
- 本研究为未来的袋炎研究奠定了基础。
常见问题
什么是袋炎？
袋炎是回肠袋的炎症，通常发生在溃疡性结肠炎手术后。
为什么使用小鼠模型研究袋炎？
小鼠模型允许对袋炎机制和治疗进行受控的研究，这在人类中难以进行。
本研究采用了什么手术技术？
本研究采用回肠-肛门吻合术（IPAA）手术。
如何在小鼠模型中诱导袋炎？
使用术后4天的4%硫酸盐右旋糖酐（DSS）治疗来诱导袋炎。
本研究的预期成果是什么？
研究旨在提供关于袋炎的发病机制和治疗选择的见解。
术后管理起到什么作用？
术后管理对于袋炎模型的成功和受试者的整体康复至关重要。
Executive Industry Relevance
Establishing a reproducible rat model of pouchitis following proctocolectomy and ileal pouch-anal anastomosis (IPAA) addresses a critical gap in preclinical research for inflammatory bowel disease complications. This model enables mechanistic de-risking and target validation for therapeutic discovery in a disease-relevant system where clinical studies are limited. Its robust design supports translational continuity from early discovery through preclinical evaluation, informing portfolio decisions for novel anti-inflammatory agents.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of pouchitis pathogenesis and immune-mediated mechanisms in a controlled in vivo context.
- Supports functional target validation by recapitulating human post-surgical inflammatory responses.
- Facilitates predictive confidence in candidate selection by providing a reproducible disease model.
Screening & Assay Development
- Provides a validated animal system for quantitative assessment of drug efficacy and biomarker response.
- Standardizes endpoints such as weight loss, food intake, and histopathology for cross-study comparability.
- Enables reproducible screening of anti-inflammatory compounds in a clinically relevant setting.
Translational & Preclinical Research
- Aligns with disease-relevant pathology, supporting translational biomarker discovery and validation.
- Bridges early mechanistic findings to preclinical proof-of-concept for pouchitis interventions.
- Reduces translational risk by modeling post-surgical inflammatory complications observed in UC patients.
Pipeline & Workflow Integration
This rat pouchitis model integrates into the discovery-to-preclinical continuum, enabling hypothesis testing, lead identification, and translational validation for anti-inflammatory therapeutics targeting post-colectomy complications.
- Discovery Biology: Supports mechanistic studies of immune and inflammatory pathways implicated in pouchitis.
- Screening: Delivers quantitative, reproducible outputs for compound efficacy and safety profiling.
- Analytics: Provides standardized readouts including weight, intake metrics, and tissue pathology for robust statistical analysis.
- Translational Research: Facilitates alignment of preclinical findings with clinical pouchitis pathology and biomarker profiles.
- Enterprise Reuse: Establishes a reusable platform for iterative drug and biomarker evaluation across discovery programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in pouchitis drug discovery.
- Operational Value: Enhances standardization, reproducibility, and scalability of preclinical inflammatory disease models.
- Strategic Value: Informs go/no-go decisions and optimizes resource allocation by de-risking early-stage candidates.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of anti-inflammatory assets targeting post-surgical complications.
Implementation Considerations
- Requires expertise in microsurgical techniques and post-operative animal care.
- Demands access to specialized instrumentation for IPAA surgery and DSS administration.
- Necessitates cross-team standardization of endpoints and analytical protocols.
- Adaptation may be needed for different rodent strains or pouchitis-inducing agents.
- Model limitations include surgical complexity and the need for rigorous post-operative monitoring.
Biopharma FAQs
Why does null hypothesis testing matter for pouchitis target validation?
Null hypothesis testing in this rat pouchitis model enables objective evaluation of whether candidate interventions significantly alter disease endpoints such as weight loss, histopathology, or inflammatory markers, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation fit the pouchitis discovery pipeline?
By controlling variables such as DSS exposure and surgical technique, the model isolates the effects of specific interventions, allowing teams to attribute observed changes in pouchitis pathology directly to the tested compound or mechanism, streamlining the discovery pipeline.
What do quantitative dependent variable measurements enable in pouchitis studies?
Quantitative measurements of weight, intake, and tissue pathology provide reproducible endpoints for comparing intervention groups, enabling statistical rigor and facilitating cross-study and cross-team data integration in preclinical pouchitis research.
Why are replication requirements critical for cross-functional pouchitis research?
Replication ensures that observed effects in the pouchitis model are consistent and reproducible, which is essential for cross-functional collaboration, data reliability, and advancing candidates through the R&D pipeline with confidence.
What statistical analysis capabilities are required before implementing pouchitis model outputs?
Robust statistical analysis, including group comparisons and significance testing of endpoints like weight and histopathology, is required to validate findings and support data-driven decisions for candidate progression in biopharma pipelines.
